Saturday 17 October 2026
Export NAGE’s income statement to Excel — free account
Niagen Bioscience, Inc.
NAGE Healthcare Biotechnology
Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024. In the quarter to June 2026, revenue fell 4.28%, EPS fell 80.0% and free cash flow grew 140.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
2.49
0.09
−3.49%
Follow NAGE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 4 | 4 | 4 | 3 | 3 | 6 | 8 | 6 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.40 | 27.65 |
Altman Z-Score |
5.40 | 16.85 | 3.33 | 2.34 | 3.17 | 1.95 | (1.20) | (0.61) | 9.82 | 10.54 |
P/S ratio |
5.94 | 13.36 | 5.98 | 5.31 | 4.95 | 3.73 | 1.64 | 1.28 | 4.05 | 3.89 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.42 | 33.74 | 38.17 |
Altman Z″-Score (non-manufacturers) |
(5.10) | 6.80 | (6.88) | (11.01) | (12.05) | (7.84) | (8.83) | (7.40) | (1.31) | 3.42 |
P/Operating CF |
672.93 | (75.18) | (36.73) | (403.13) | 13,323.71 | (50.82) | (359.27) | 165.22 | 46.97 | 741.64 |
Beneish M-Score |
0.15 | (3.29) | (4.27) | (3.97) | (3.39) | (1.81) | (2.04) | (3.96) | (2.36) | (1.55) |
P/B ratio |
12.90 | 5.26 | 6.94 | 12.03 | 17.85 | 7.92 | 4.11 | 3.77 | 8.75 | 6.58 |
Price to Tangible BV |
13.56 | 5.43 | 7.36 | 12.85 | 19.11 | 8.14 | 4.21 | 3.84 | 8.82 | 7.11 |
EV/Sales |
5.97 | 11.32 | 5.33 | 4.95 | 4.70 | 3.40 | 1.38 | 0.98 | 3.62 | 3.40 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.20 | 25.82 |
EV/Operating CF |
(44.01) | (24.48) | (8.04) | (11.20) | (26.26) | (9.48) | (6.58) | 11.49 | 29.76 | 32.63 |
EV/FCF |
(27.72) | (46.13) | (7.52) | (11.09) | (25.91) | (9.32) | (6.43) | 11.76 | 30.16 | 33.40 |
Quick Ratio |
0.85 | 6.27 | 1.92 | 1.39 | 1.18 | 1.90 | 1.62 | 1.58 | 2.92 | 3.74 |
Current Ratio |
1.77 | 7.07 | 2.53 | 2.23 | 1.96 | 2.78 | 2.61 | 2.40 | 3.57 | 4.86 |
Net Debt/EBITDA |
0.52 | 2.88 | 0.70 | 0.64 | 0.89 | 0.93 | 1.16 | 5.98 | (5.23) | (3.80) |
Debt/Assets |
1.74% | 0.49% | 0.32% | 0.04% | 0.05% | 7.18% | 0.04% | 0.02% | 0.00% | 0.00% |
Debt/Equity |
0.03 | 0.01 | 0.01 | 0.00 | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
1.13 | 0.51 | 0.60 | 1.12 | 1.51 | 1.40 | 1.29 | 1.53 | 1.62 | 1.48 |
Operating CF/Net income |
1.00 | 0.86 | 0.63 | 0.64 | 0.53 | 0.89 | 0.91 | (1.44) | 1.42 | 0.78 |
Capex/Depreciation |
(4.11) | 6.43 | (1.72) | (0.11) | (0.13) | (0.37) | (0.32) | (0.14) | (0.18) | (0.37) |
Interest Coverage |
(8.72) | (107.04) | (419.90) | (36.95) | (279.63) | (492.24) | 6,209.33 | — | — | — |
| (38.40%) | (35.66%) | (82.25%) | (135.01%) | (108.09%) | (112.68%) | (54.77%) | (17.29%) | 22.94% | 28.35% | |
| (15.21%) | (27.59%) | (63.49%) | (77.95%) | (50.70%) | (56.40%) | (29.56%) | (9.06%) | 13.88% | 19.90% | |
ROIC |
(20.93%) | (116.91%) | (441.21%) | (1,184.89%) | 0.00% | (220.84%) | (141.07%) | (306.16%) | 336.73% | 86.63% |
Return on Tangible Assets |
(33.87%) | (21.90%) | (129.74%) | (144.68%) | (105.15%) | (79.10%) | (52.51%) | (15.90%) | 17.86% | 22.22% |
Average Days of Receivables |
98.59 | 91.90 | 58.25 | 17.15 | 16.59 | 28.28 | 42.97 | 22.86 | 28.47 | 27.47 |
Research and Development Expense of Revenue |
11.64% | 18.90% | 17.36% | 9.55% | 5.76% | 5.68% | 6.70% | 5.93% | 6.04% | 4.89% |
Selling, General and Administrative Expense of Revenue |
49.73% | 104.25% | 138.40% | 113.46% | 87.27% | 95.97% | 78.56% | 61.53% | 48.04% | 48.34% |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.04 | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 |
Share Based Compensation of Revenue |
5.51% | 21.72% | 20.19% | 15.49% | 11.70% | 9.18% | 7.97% | 5.69% | 3.67% | 4.69% |
Graham Net Nets |
0.05 | 0.17 | 0.11 | 0.06 | 0.04 | 0.09 | 0.18 | 0.21 | 0.10 | 0.13 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.19 | 2.24 |
Earnings Yield |
(2.48%) | (3.78%) | (17.78%) | (12.99%) | (6.88%) | (10.96%) | (13.87%) | (4.78%) | 1.95% | 3.62% |
Free Cash Flow Yield |
(3.62%) | (1.84%) | (11.85%) | (8.39%) | (3.66%) | (9.79%) | (13.11%) | 6.49% | 2.96% | 2.62% |
Revenue per Share |
0.58 | 0.48 | 0.57 | 0.81 | 0.97 | 1.00 | 1.03 | 1.11 | 1.31 | 1.63 |
Operating CF per Share |
(0.08) | (0.22) | (0.38) | (0.36) | (0.17) | (0.36) | (0.22) | 0.09 | 0.16 | 0.17 |
Capex per Share |
(0.05) | 0.10 | (0.03) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.12) | (0.12) | (0.41) | (0.36) | (0.18) | (0.37) | (0.22) | 0.09 | 0.16 | 0.17 |
Cash per Share |
0.04 | 1.02 | 0.41 | 0.33 | 0.27 | 0.42 | 0.29 | 0.36 | 0.59 | 0.82 |
Shareholders Equity per Share |
0.27 | 1.21 | 0.49 | 0.36 | 0.27 | 0.47 | 0.41 | 0.38 | 0.61 | 0.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.27 | 1.21 | 0.49 | 0.36 | 0.27 | 0.47 | 0.41 | 0.38 | 0.61 | 0.97 |
Free Cash Flow |
(4.66) | (5.20) | (22.36) | (20.64) | (10.74) | (24.57) | (15.43) | 6.97 | 11.97 | 13.21 |
Working Capital |
6.87 | 49.09 | 22.09 | 18.46 | 15.74 | 31.29 | 28.70 | 28.91 | 46.15 | 76.89 |
Capital Expenditures |
(1.72) | 4.60 | (1.45) | (0.20) | (0.14) | (0.41) | (0.33) | (0.14) | (0.14) | (0.29) |
Net Current Asset Value |
5.96 | 48.29 | 21.48 | 13.72 | 10.29 | 22.79 | 21.18 | 23.03 | 41.92 | 66.93 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.65 | 27.07 |
Capex to Sales |
0.08 | (0.22) | 0.05 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 52.19 | 30.93 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.24 | 0.25 | 0.23 | 0.49 | 0.35 | 0.37 | 0.38 | 0.48 | 0.47 | 0.59 |
Cash ROIC |
(38.97%) | (5.23%) | (44.78%) | (52.55%) | (32.41%) | (38.33%) | (31.41%) | 12.50% | 13.19% | 9.35% |
Accounts Receivable Turnover |
5.22 | 3.79 | 6.08 | 12.84 | 24.34 | 17.03 | 10.51 | 12.19 | 15.32 | 14.78 |
Accounts Payable Turnover |
1.85 | 2.21 | 2.34 | 2.14 | 2.52 | 2.61 | 2.91 | 3.29 | 4.05 | 4.79 |
Inventory Turnover |
1.40 | 1.56 | 2.21 | 2.07 | 2.07 | 2.05 | 2.07 | 2.25 | 3.21 | 3.12 |
Average Days of Payables |
193.55 | 126.58 | 224.81 | 171.21 | 143.74 | 146.55 | 120.77 | 113.90 | 81.87 | 85.23 |
Days of Inventory on Hand |
256.17 | 197.27 | 194.23 | 205.16 | 177.80 | 191.24 | 183.13 | 161.68 | 88.27 | 161.24 |
Average Receivables |
4.15 | 5.60 | 5.19 | 3.61 | 2.43 | 3.96 | 6.85 | 6.86 | 6.50 | 8.75 |
Average Payables |
6.10 | 4.85 | 6.63 | 9.59 | 9.54 | 9.93 | 10.05 | 9.96 | 9.38 | 9.66 |
Average Inventory |
8.04 | 6.85 | 7.02 | 9.89 | 11.61 | 12.64 | 14.14 | 14.60 | 11.86 | 14.81 |
Average Assets |
19.25 | 41.24 | 52.48 | 41.24 | 39.30 | 48.10 | 55.95 | 54.51 | 61.62 | 87.34 |
Average Common Equity |
7.62 | 31.90 | 40.51 | 23.81 | 18.43 | 24.08 | 30.20 | 28.56 | 37.28 | 61.31 |
Columns are period end dates